Electra Therapeutics closes $350M IPO at $15
Electra Therapeutics completes a Nasdaq IPO, raising about $350 million and implementing restated charter and bylaws.
Rhea-AI Filing Summary
Electra Therapeutics, Inc. (ETRA) reported the closing of its initial public offering of common stock on September 21, 2026. The company sold 23,333,334 shares of common stock at $15.00 per share, generating approximately $350.0 million in gross proceeds before underwriting discounts and expenses.
In connection with the IPO closing, Electra Therapeutics’ stockholders and board put into effect an amended and restated certificate of incorporation and amended and restated bylaws. The company’s common stock trades on The Nasdaq Global Select Market under the symbol ETRA.
Positive
- Raised approximately $350.0 million in gross proceeds from the IPO, providing substantial new capital to the company.
- Completed a Nasdaq Global Select Market listing under symbol ETRA, which can enhance trading liquidity and visibility.
- Implemented amended and restated certificate of incorporation and bylaws, aligning corporate governance with public company status.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
3 items: 5.03, 8.01, 9.01
3 items
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Shares sold in IPO: 23,333,334 shares
IPO price per share: $15.00 per share
Gross IPO proceeds: $350.0 million
+2 more
5 metrics
Shares sold in IPO
23,333,334 shares
Aggregate number of common shares sold in the IPO closed September 21, 2026
IPO price per share
$15.00 per share
Public offering price of Electra Therapeutics common stock in the IPO
Gross IPO proceeds
$350.0 million
Aggregate gross proceeds before underwriting discounts, commissions and expenses
IPO closing date
September 21, 2026
Date on which the IPO closed and governance changes became effective
Trading symbol
ETRA
Ticker for Electra Therapeutics common stock on The Nasdaq Global Select Market
Key Terms
initial public offering, amended and restated certificate of incorporation, Restated Bylaws, Rule 424(b), +1 more
5 terms
initial public offering financial
"in connection with the closing of the initial public offering (the “IPO”)"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
amended and restated certificate of incorporation regulatory
"the Company filed an amended and restated certificate of incorporation"
A company’s amended and restated certificate of incorporation is an updated version of its foundational legal charter that replaces the older document and folds in all changes into one clear copy; it spells out corporate structure, classes of stock, shareholder rights and key governance rules. Investors care because it can change who controls the company, how votes are counted, what claims shareholders have on assets or dividends, and can introduce or remove protections against takeovers—like updating a house title after a major renovation to show who owns what and under what rules.
Restated Bylaws regulatory
"the Company adopted amended and restated bylaws (the “Restated Bylaws”)"
Rule 424(b) regulatory
"filed with the U.S. Securities and Exchange Commission on September 18, 2026 pursuant to Rule 424(b)"
Rule 424(b) is a U.S. Securities and Exchange Commission requirement that companies file the exact prospectus or prospectus supplement they use to sell securities after a registration statement becomes effective. Think of it as the official posting of the final sales brochure so investors can see the precise terms, risks and use of proceeds; it matters because it ensures transparency, helps investors compare offerings and confirms the issuer complied with disclosure rules.
Registration Statement on Form S-1 regulatory
"relating to the Registration Statement on Form S-1, as amended"
A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Electra Therapeutics (ETRA) announce in this Form 8-K?
Electra Therapeutics announced the closing of its initial public offering of common stock and the effectiveness of its amended and restated certificate of incorporation and amended and restated bylaws in connection with becoming a public company.
How much capital did Electra Therapeutics (ETRA) raise in its IPO?
Electra Therapeutics raised approximately $350.0 million in gross proceeds from its IPO, before deducting underwriting discounts, commissions, and offering expenses, by selling 23,333,334 shares of common stock at $15.00 per share.
What were the key terms of Electra Therapeutics’ IPO pricing?
The IPO consisted of 23,333,334 shares of Electra Therapeutics common stock priced at $15.00 per share to the public, resulting in aggregate gross proceeds of about $350.0 million before fees and expenses payable by the company.
On which exchange is Electra Therapeutics (ETRA) listed and under what symbol?
Electra Therapeutics’ common stock is listed on The Nasdaq Global Select Market under the trading symbol ETRA, as disclosed in the securities registration section.
What corporate governance changes did Electra Therapeutics (ETRA) implement at IPO closing?
Effective September 21, 2026, Electra Therapeutics put into effect an amended and restated certificate of incorporation and amended and restated bylaws, previously approved by its board and stockholders, in connection with the IPO closing.
Where can investors find more detail on Electra Therapeutics’ capital structure after the IPO?
Further detail on Electra Therapeutics’ capital structure and governance is provided in the “Description of Capital Stock” section of the final prospectus filed on September 18, 2026 pursuant to Rule 424(b) under the Securities Act.
AI-generated analysis. How Rhea-AI works. Not financial advice.
